Mối quan hệ giữa kháng thể tự động chống lại thụ thể TSH trong huyết thanh (TRAbs) và các đặc điểm lâm sàng của bệnh mắt Graves

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European thyroid association/european group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26 Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 36:444–449 Leo M, Menconi F, Rocchi R, Latrofa F, Sisti E, Profilo MA, Mazzi B, Albano E, Nardi M, Vitti P, Marcocci C, Marinò M (2015) Role of the underlying thyroid disease on the phenotype of graves’ orbitopathy in a tertiary referral center. Thyroid 25:347–351 Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362:726–738 Bahn RS (2015) Current insights into the Pathogenesis of Graves’ Ophthalmopathy. Horm Metab Res 47:773–778 Marinò M, Chiovato L, Lisi S, Altea MA, Marcocci C, Pinchera A (2004) Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: the hypothesis of Kriss revisited. J Endocrinol Invest 27:230–236 Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE (1998) Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J Clin Endocrinol Metab 83:998–1002 Ludgate M, Crisp M, Lane C et al (1998) The thyrotropin receptor in thyroid eye disease. Thyroid 8:411–413 Bahn RS, Dutton CM, Joba W, Heufelder AE (1998) Thyrotropin receptor expression in cultured Graves’ orbital preadipocyte fibroblasts is stimulated by thyrotropin. Thyroid 8:193–196 Wakelkamp IMMJ, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF (2003) TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrinol (Oxf) 58:280–287 Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS (2011) A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves’ ophthalmopathy. J Mol Endocrinol 46:155–163 Gerding MN, Van Der Meer JWC, Broenink M, Bakker O, Wiersinga WM, Prummel MF et al (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 52:267–271 Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ (2010) A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of graves’ orbitopathy. J Clin Endocrinol Metab 95:2123–2131 Eckstein AK, Plicht M, Lax H et al (2006) Thyrotropin receptor autoantibodies are independent risk factors for graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470 Noh JY, Hamada N, Inoue Y, Abe Y, Ito K, Ito K (2000) Thyroid-stimulating antibody is related to Graves’ ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves’ disease. Thyroid 10:809–813 Mukasa K, Noh JY, Kouzaki A et al (2016) TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves’ ophthalmopathy in untreated Japanese Graves’ disease patients. Endocr J 63:151–157 Woo YJ, Jang SY, Lim THT, Yoon JS (2015) Clinical association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of Graves’ orbitopathy. Korean J Ophthalmol 29:213–219 Seo S, Sánchez Robledo M (2018) Usefulness of TSH receptor antibodies as biomarkers for Graves’ ophthalmopathy: a systematic review. J Endocrinol Invest 41:1457–1468 Hesarghatta Shyamasunder A, Abraham P (2017) Measuring TSH receptor antibody to influence treatment choices in Graves’ disease. Clin Endocrinol (Oxf) 86:652–657 Lytton SD, Kahaly GJ (2010) Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev 10:116–122 Kahaly GJ (2015) Bioassays for TSH receptor antibodies: quo vadis? Eur Thyroid J 4:3–5 Khoo DH, Eng PH, Ho SC et al (2000) Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 10:1093–1100 Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, König J (2016) Thyroid stimulating antibodies are highly prevalent in Hashimoto’s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab 101:1998–2004 Mourits MP, Lombardo SHC, Van Der Sluijs FA, Fenton S (2004) Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves’ patients. An exploratory study. Orbit 23:161–168 Bilen H, Gullulu G, Akcay G (2007) Exophthalmometric values in a normal Turkish population living in the northeastern part of Turkey. Thyroid 17:525–528 Kashkouli MB, Nojomi M, Parvaresh MM, Sanjari MS, Modarres M, Noorani MM (2008) Normal values of hertel exophthalmometry in children, teenagers, and adults from Tehran. Iran Optom Vis Sci 85:1012–1017 Beden Ü, Özarslan Y, Öztürk HE, Sönmez B, Erkan D, Oge I (2008) Exophthalmometry values of Turkish adult population and the effect of age, sex, refractive status, and Hertel base values on Hertel readings. Eur J Ophthalmol 18:165–171 Chan WO, Madge SN, Senaratne T et al (2009) Exophthalmometric values and their biometric correlates: the Kandy eye study. Clin Exp Ophthalmol 37:496–502 Profilo MA, Sisti E, Marcocci C et al (2013) Thyroid volume and severity of graves’ orbitopathy. Thyroid 23:97–102 Bartalena L, Baldeschi L, Dickinson A et al (2008) Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285 Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47:9–14 Dolman PJ (2012) Evaluating Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab 26:229–248 Dolman PJ, Rootman J (2006) VISA classification for graves orbitopathy. Ophthal Plast Reconstr Surg 22:319–324 Wiersinga WM, Prummel MF, Mourits MP, Koornneef L, Buller HR (1991) Classification of the eye changes of Graves’ disease. Thyroid 1:357–360 Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ (2011) Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology 118:2279–2285 Jang SY, Shin DY, Lee EJ, Choi YJ, Lee SY, Yoon JS (2013) Correlation between TSH receptor antibody assays and clinical manifestations of Graves’ orbitopathy. Yonsei Med J 54:1033–1039 Rotondi M, Virili C, Pinto S et al (2020) The clinical phenotype of Graves’ disease occurring as an isolated condition or in association with other autoimmune diseases. J Endocrinol Invest 43:157–162 Menconi F, Profilo MA, Leo M et al (2014) Spontaneous improvement of untreated mild Graves’ ophthalmopathy: Rundle’s curve revisited. Thyroid 24:60–66 Hai YP, Lee ACH, Frommer L, Diana T, Kahaly GJ (2019) Immonoistochemical analysis of human orbital tissue in Graves’ orbitopathy. J Endocrinol Invest 43:123–137